

## Profile 85

### Investment objective

To maximise capital growth over the long term with a little emphasis on the level of income, utilising a diversified portfolio with a stronger bias to growth asset classes such as Australian and international shares.

Features	Information
APIR code	PBT0005AU
Minimum suggested investment time frame	6 years
Benchmark	Composite benchmark
Income distribution frequency	Half yearly (as at 30 June and 31 December)
Fund size	\$5.38m

Total estimated management costs as at 30/06/2021 <sup>1</sup>	
Estimated management fee	0.82% pa
Estimated performance fee	Nil
Total estimated management cost	0.82% pa

### Performance <sup>2</sup>

	3 mths %	6 mths %	1 year %	3 years % pa	5 years % pa
Total return	-1.55	2.17	9.83	8.97	8.13
Benchmark	-2.59	0.90	9.71	10.14	9.37

Performance data provided by FE fundinfo.

### Investment strategy

How the scheme is managed:

The scheme is managed by IOOF QuantPlus to deliver solid consistent returns through efficient exposure to a highly diversified portfolio of assets. Simply put – proven investment managers and risk management techniques are employed to deliver a well-diversified portfolio whilst considering the optimal risk and return outcome.

The performance objective of the scheme is to achieve a gross return at least equal to the weighted average of the applicable benchmark return for each of the component asset classes over periods greater than one year.

## Top holdings - Australian shares <sup>3</sup>

BHP Group Ltd	9.78%
Commonwealth Bank of Australia	3.96%
National Australia Bank Limited	3.19%
CSL Limited	2.46%
RIO Tinto Limited	2.36%
Westpac Banking Corp	2.25%
Australia and New Zealand Banking Group Limited	2.12%
Fortescue Metals Group	1.76%
Goodman Group	1.69%
Macquarie Group	1.56%

## Top holdings - International shares

Apple Inc	2.16%
Microsoft Corporation	2.10%
Amazon Com Inc	1.20%
Facebook Inc com	0.88%
Johnson & Johnson Com	0.78%
JP Morgan Chase & Co	0.71%
Berkshire Hathaway Inc	0.71%
Verizon Communications	0.67%
NVIDIA Corporation	0.60%
UnitedHealth Group Incorporated	0.51%

1800 002 217

investorservices@ioof.com.au

www.ioof.com.au

### Notes to the trust profile

- 1 This cost may vary from time-to-time due to changes to underlying investment managers and their fees. Please refer to the latest PDS and [www.ioof.com.au](http://www.ioof.com.au) for full details on fees and costs.
- 2 Performance is net of management costs and expenses. Performance is based on exit price to exit price for the period and assumes that all distributions are reinvested. Management costs and other expenses are accounted for in the exit price. Past performance is not a reliable indicator of future performance. Please refer to [www.ioof.com.au](http://www.ioof.com.au) for updated performance information. Performance data is provided by FE fundinfo (FE fundinfo (Australia) Pty Limited, ABN 18 601 868 311). For further information visit <https://www.fe-fundinfo.com>
- 3 Information shown may include data provided by some investment managers from the prior month.

**Important information:** This document is issued by IOOF Investment Services Ltd (IISL) ABN 80 007 350 405, AFSL 230703, as Responsible Entity of the Profile Managed Investments. IISL is a company within the Insignia Financial Group of companies which consists of Insignia Financial Ltd ABN 49 100 103 722 and its related bodies corporate. IISL's contact details can be found on [www.ioof.com.au](http://www.ioof.com.au). Past performance is not a reliable indicator of future performance. The information contained in this document is believed to be correct at the time of publication, however to the extent permitted by law, no liability is accepted for any loss or damage as a result of any reliance on the information it contains. This profile is not intended to represent investment or professional advice. The information does not take into account your individual objectives, financial circumstances or needs. You should assess whether the information is appropriate for you, having regard to your objectives, financial circumstances or needs. You should consider the relevant Product Disclosure Statement (PDS) and Target Market Determination (TMD) in deciding whether to acquire or to continue to hold the investment and consider talking to a licenced or appropriately authorised financial adviser before making an investment decision.